Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

@article{Qian2006TargetingTA,
  title={Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.},
  author={David Qian and Yukihiko Kato and Shabana Shabbeer and Yongfeng Wei and Hendrik M. W. Verheul and Brenda C. Salumbides and Tolib B. Sanni and Peter W Atadja and Roberto Pili},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2006},
  volume={12 2},
  pages={634-42}
}
PURPOSE Angiogenesis is required for tumor progression and represents a rational target for therapeutic intervention. Histone deacetylase (HDAC) inhibitors have been shown to have activity against various tumor cell types by inhibiting proliferation and inducing apoptosis both in vitro and in vivo. HDAC inhibitors have also been reported to inhibit angiogenesis. The goal of this study was to characterize the antiangiogenic and antitumor activity of a recently developed HDAC inhibitor, the… CONTINUE READING
106 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 106 extracted citations

Similar Papers

Loading similar papers…